|Dr. Clay B. Siegall||Co-Founder, Chairman, Pres & CEO||2.88M||19.58M||1961|
|Mr. Todd E. Simpson||Chief Financial Officer||1.11M||N/A||1961|
|Ms. Jean I. Liu||Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.||1M||N/A||1968|
|Dr. Roger D. Dansey M.D.||Chief Medical Officer||1.74M||535.65k||1957|
|Dr. Vaughn B. Himes||Chief Technology Officer||N/A||N/A||1961|
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seattle Genetics, Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and biotechnology and pharmaceutical companies. Seattle Genetics, Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Seattle Genetics, Inc.’s ISS governance QualityScore as of 5 December 2019 is 4. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 5; Compensation: 2.